Cargando…

Facilitators of and barriers to buprenorphine initiation for people with opioid use disorder in the emergency department: protocol for a scoping review

INTRODUCTION: Buprenorphine–naloxone is recommended as a first-line agent for the treatment of opioid use disorder. Although initiation of buprenorphine in the emergency department (ED) is evidence based, barriers to implementation persist. A comprehensive review and critical analysis of both facili...

Descripción completa

Detalles Bibliográficos
Autores principales: Bozinoff, Nikki, Soobiah, Charlene, Rodak, Terri, Bucago, Christine, Kingston, Katie, Klaiman, Michelle, Poynter, Brittany, Samuels, Glenna, Schoenfeld, Elizabeth, Shelton, Dominick, Kalocsai, Csilla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477333/
https://www.ncbi.nlm.nih.gov/pubmed/34580102
http://dx.doi.org/10.1136/bmjopen-2021-053207
_version_ 1784575821178994688
author Bozinoff, Nikki
Soobiah, Charlene
Rodak, Terri
Bucago, Christine
Kingston, Katie
Klaiman, Michelle
Poynter, Brittany
Samuels, Glenna
Schoenfeld, Elizabeth
Shelton, Dominick
Kalocsai, Csilla
author_facet Bozinoff, Nikki
Soobiah, Charlene
Rodak, Terri
Bucago, Christine
Kingston, Katie
Klaiman, Michelle
Poynter, Brittany
Samuels, Glenna
Schoenfeld, Elizabeth
Shelton, Dominick
Kalocsai, Csilla
author_sort Bozinoff, Nikki
collection PubMed
description INTRODUCTION: Buprenorphine–naloxone is recommended as a first-line agent for the treatment of opioid use disorder. Although initiation of buprenorphine in the emergency department (ED) is evidence based, barriers to implementation persist. A comprehensive review and critical analysis of both facilitators of and barriers to buprenorphine initiation in ED has yet to be published. Our objectives are (1) to map the implementation of buprenorphine induction pathway literature and synthesise what we know about buprenorphine pathways in EDs and (2) to identify gaps in this literature with respect to barriers and facilitators of implementation. METHODS AND ANALYSIS: We will conduct a scoping review to comprehensively search the literature, map the evidence and identify gaps in knowledge. The review will adhere to the Preferred Reporting Items for Systematic Reviews and Meta-analyses Protocols Extension for Scoping Reviews and guidance from the Joanna Briggs Institution for conduct of scoping reviews. We will search Medline, APA, PsycINFO, CINAHL, Embase and IBSS from 1995 to present and the search will be restricted to English and French language publications. Citations will be screened in Covidence by two trained reviewers. Discrepancies will be mediated by consensus. Data will be synthesised using a hybrid, inductive–deductive approach, informed by the Consolidated Framework for Implementation Research as well as critical theory to guide further interpretation. ETHICS AND DISSEMINATION: This review does not require ethics approval. A group of primary knowledge users, including clinicians and people with lived experience, will be involved in the dissemination of findings including publication in peer-reviewed journals. Results will inform future research, current quality improvement efforts in affiliated hospitals, and aide the creation of a more robust ED response to the escalating overdose crisis.
format Online
Article
Text
id pubmed-8477333
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-84773332021-10-08 Facilitators of and barriers to buprenorphine initiation for people with opioid use disorder in the emergency department: protocol for a scoping review Bozinoff, Nikki Soobiah, Charlene Rodak, Terri Bucago, Christine Kingston, Katie Klaiman, Michelle Poynter, Brittany Samuels, Glenna Schoenfeld, Elizabeth Shelton, Dominick Kalocsai, Csilla BMJ Open Addiction INTRODUCTION: Buprenorphine–naloxone is recommended as a first-line agent for the treatment of opioid use disorder. Although initiation of buprenorphine in the emergency department (ED) is evidence based, barriers to implementation persist. A comprehensive review and critical analysis of both facilitators of and barriers to buprenorphine initiation in ED has yet to be published. Our objectives are (1) to map the implementation of buprenorphine induction pathway literature and synthesise what we know about buprenorphine pathways in EDs and (2) to identify gaps in this literature with respect to barriers and facilitators of implementation. METHODS AND ANALYSIS: We will conduct a scoping review to comprehensively search the literature, map the evidence and identify gaps in knowledge. The review will adhere to the Preferred Reporting Items for Systematic Reviews and Meta-analyses Protocols Extension for Scoping Reviews and guidance from the Joanna Briggs Institution for conduct of scoping reviews. We will search Medline, APA, PsycINFO, CINAHL, Embase and IBSS from 1995 to present and the search will be restricted to English and French language publications. Citations will be screened in Covidence by two trained reviewers. Discrepancies will be mediated by consensus. Data will be synthesised using a hybrid, inductive–deductive approach, informed by the Consolidated Framework for Implementation Research as well as critical theory to guide further interpretation. ETHICS AND DISSEMINATION: This review does not require ethics approval. A group of primary knowledge users, including clinicians and people with lived experience, will be involved in the dissemination of findings including publication in peer-reviewed journals. Results will inform future research, current quality improvement efforts in affiliated hospitals, and aide the creation of a more robust ED response to the escalating overdose crisis. BMJ Publishing Group 2021-09-27 /pmc/articles/PMC8477333/ /pubmed/34580102 http://dx.doi.org/10.1136/bmjopen-2021-053207 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Addiction
Bozinoff, Nikki
Soobiah, Charlene
Rodak, Terri
Bucago, Christine
Kingston, Katie
Klaiman, Michelle
Poynter, Brittany
Samuels, Glenna
Schoenfeld, Elizabeth
Shelton, Dominick
Kalocsai, Csilla
Facilitators of and barriers to buprenorphine initiation for people with opioid use disorder in the emergency department: protocol for a scoping review
title Facilitators of and barriers to buprenorphine initiation for people with opioid use disorder in the emergency department: protocol for a scoping review
title_full Facilitators of and barriers to buprenorphine initiation for people with opioid use disorder in the emergency department: protocol for a scoping review
title_fullStr Facilitators of and barriers to buprenorphine initiation for people with opioid use disorder in the emergency department: protocol for a scoping review
title_full_unstemmed Facilitators of and barriers to buprenorphine initiation for people with opioid use disorder in the emergency department: protocol for a scoping review
title_short Facilitators of and barriers to buprenorphine initiation for people with opioid use disorder in the emergency department: protocol for a scoping review
title_sort facilitators of and barriers to buprenorphine initiation for people with opioid use disorder in the emergency department: protocol for a scoping review
topic Addiction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477333/
https://www.ncbi.nlm.nih.gov/pubmed/34580102
http://dx.doi.org/10.1136/bmjopen-2021-053207
work_keys_str_mv AT bozinoffnikki facilitatorsofandbarrierstobuprenorphineinitiationforpeoplewithopioidusedisorderintheemergencydepartmentprotocolforascopingreview
AT soobiahcharlene facilitatorsofandbarrierstobuprenorphineinitiationforpeoplewithopioidusedisorderintheemergencydepartmentprotocolforascopingreview
AT rodakterri facilitatorsofandbarrierstobuprenorphineinitiationforpeoplewithopioidusedisorderintheemergencydepartmentprotocolforascopingreview
AT bucagochristine facilitatorsofandbarrierstobuprenorphineinitiationforpeoplewithopioidusedisorderintheemergencydepartmentprotocolforascopingreview
AT kingstonkatie facilitatorsofandbarrierstobuprenorphineinitiationforpeoplewithopioidusedisorderintheemergencydepartmentprotocolforascopingreview
AT klaimanmichelle facilitatorsofandbarrierstobuprenorphineinitiationforpeoplewithopioidusedisorderintheemergencydepartmentprotocolforascopingreview
AT poynterbrittany facilitatorsofandbarrierstobuprenorphineinitiationforpeoplewithopioidusedisorderintheemergencydepartmentprotocolforascopingreview
AT samuelsglenna facilitatorsofandbarrierstobuprenorphineinitiationforpeoplewithopioidusedisorderintheemergencydepartmentprotocolforascopingreview
AT schoenfeldelizabeth facilitatorsofandbarrierstobuprenorphineinitiationforpeoplewithopioidusedisorderintheemergencydepartmentprotocolforascopingreview
AT sheltondominick facilitatorsofandbarrierstobuprenorphineinitiationforpeoplewithopioidusedisorderintheemergencydepartmentprotocolforascopingreview
AT kalocsaicsilla facilitatorsofandbarrierstobuprenorphineinitiationforpeoplewithopioidusedisorderintheemergencydepartmentprotocolforascopingreview